Last reviewed · How we verify
NCT05450939
Characteristics of Signal Intensity Gradient in Subarachnoid Hemorrhage After Aneurysmal Rupture
trial testing Signal intensity gradient in Aneurysmal Rupture in 80 participants. Status unknown.
31 July 2023
Quick facts
| Lead sponsor | Chonbuk National University Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 80 |
| Start date | 25 November 2021 |
| Primary completion | 31 July 2023 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Signal intensity gradient
Conditions studied
- Aneurysmal Rupture — all drugs for Aneurysmal Rupture →
Sponsor
Chonbuk National University Hospital
Who can join
18 and older, any sex, with Aneurysmal Rupture. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
10-20% of patients with subarachnoid hemorrhage die before they arrive at the hospital, and about 25% die within 24 hours. About 1% of patients are diagnosed with cerebral aneurysms in imaging tests for health checkups, and many of them experience aneurysmal rupture during their lifetime, so it is not a rare disease. Wall shear stress is known to be a factor that reflects the state of blood vessels, and particularly plays an important role in the patency of the intima of blood vessels. In the meantime, computed fluid dynamics (CFD), a representative method for calculating wall shear stress, assumes a virtual rigid pipe and applies a preset value. This does not accurately reflect the physiological and dynamic state of the actual blood vessel. The investigators intend to measure the patient's wall shear stress using the SIG of the MRA-TOF technique, which reflects the physiological characteristics of individual patients, and to analyze the association with rupture of the intracranial aneurysm.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Geometric versus Hemodynamic Indexes for Rupture-Destined Aneurysms: A Retrospective Cohort and a Repeated-Measures Study.
Lee CH, Kwak HS, Kang HS, Jung KH, et al · · 2024 · cited 4× · PMID 37696264 · DOI 10.1159/000533167 -
Geometric versus hemodynamic indexes for rupture-destined aneurysms: a retrospective cohort and a repeated-measures study
Lee C, Kwak H, Kang H, Jung K, et al · · 2023 · DOI 10.1101/2023.02.23.23286386
Verify or expand the search:
- PubMed search for NCT05450939
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Signal intensity gradient
Trials testing the same drug.
- NCT05495191 — Signal Intensity Gradient in Cerebral Arteries · completed
- NCT04585971 — A Study on Hemodynamic Relationship Including Cerebral Blood Flow Using Phase Contrast and Signal Intensity Gradient of · unknown
Other Chonbuk National University Hospital trials
Trials by the same sponsor.
- NCT05324800 — the Efficacy and Safety of Curcuma Longa Extract Mixture on Immune Enhancement · NA · unknown
- NCT05190237 — the Efficacy and Safety of Fermented Soybean(Doenjang Powder) on Intestinal Microflora and Immune Enhancement. · NA · completed
- NCT05495191 — Signal Intensity Gradient in Cerebral Arteries · completed
- NCT04940910 — The Efficacy and Safety of Black Rice Bran Extract on Immune Enhancement · NA · unknown
- NCT04930640 — The Efficacy and Safety of SGF200 on Immune Enhancement · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05450939 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chonbuk National University Hospital
- Last refreshed: 11 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05450939.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing